An image-based high-content screening assay for compounds targeting intracellular leishmania donovani amastigotes in human macrophages

PLoS Neglected Tropical Diseases

Volumn 6, Issue 6, 2012, Pages

  Siqueira Neto, Jair L ^a   Moon, Seunghyun ^b   Jang, Jiyeon ^c   Yang, Gyongseon ^a   Lee, Changbok ^b   Moon, Hong Kee ^b   Chatelain, Eric ^d   Genovesio, Auguste ^b,e   Cechetto, Jonathan ^c   Freitas Junior, Lucio H ^a  

^a Institute Pasteur Korea   (South Korea)

^b Image Mining Group   (South Korea)

^c Institut Pasteur Korea   (South Korea)

^d Drugs for Neglected Diseases initiative DNDi   (Switzerland)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; MILTEFOSINE; PAROMOMYCIN; STIBOGLUCONATE SODIUM; ANTIPROTOZOAL AGENT; DNA;

ALGORITHM; AMASTIGOTE; ANIMAL CELL; ARTICLE; CELL DIVISION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DEVELOPMENT; DRUG TARGETING; FLUORESCENCE MICROSCOPY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMAGE ANALYSIS; INFECTION RATE; LEISHMANIA DONOVANI; LEISHMANIASIS; MACROPHAGE; NONHUMAN; PROMASTIGOTE; PROTIST LIFE CYCLE STAGE; QUALITY CONTROL; AUTOMATION; CELL LINE; DRUG EFFECT; IMAGE PROCESSING; ISOLATION AND PURIFICATION; METHODOLOGY; PARASITOLOGY; STAINING;

ANTIPROTOZOAL AGENTS; AUTOMATION; CELL LINE; DNA; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LEISHMANIA DONOVANI; MACROPHAGES; MICROSCOPY, CONFOCAL; STAINING AND LABELING;

EID: 84863673241     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001671     Document Type: Article

References (35)

1. Antoine JC, Prina E, Courret N, Lang T, (2004) Leishmania spp.: on the interactions they establish with antigen-presenting cells of their mammalian hosts. Adv Parasitol 58: 1-68.
2. (1990) Control of the leishmaniases. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 793: 1-158.
3. de Oliveira CI, Nascimento IP, Barral A, Soto M, Barral-Netto M, (2009) Challenges and perspectives in vaccination against leishmaniasis. Parasitol Int 58: 319-324.
4. Alvar J, Croft S, Olliaro P, (2006) Chemotherapy in the treatment and control of leishmaniasis. Adv Parasitol 61: 223-274.
5. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, et al. (2007) Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol 5: 873-882.
6. Croft SL, Seifert K, Yardley V, (2006) Current scenario of drug development for leishmaniasis. Indian J Med Res 123: 399-410.
7. Murray HW, Berman JD, Davies CR, Saravia NG, (2005) Advances in leishmaniasis. Lancet 366: 1561-1577.
8. Bleicher KH, Bohm HJ, Muller K, Alanine AI, (2003) Hit and lead generation: beyond high-throughput screening. Nat Rev Drug Discov 2: 369-378.
9. St George S, Bishop JV, Titus RG, Selitrennikoff CP, (2006) Novel compounds active against Leishmania major. Antimicrob Agents Chemother 50: 474-479.
10. Shimony O, Jaffe CL, (2008) Rapid fluorescent assay for screening drugs on Leishmania amastigotes. J Microbiol Methods 75: 196-200.
11. Sharlow ER, Close D, Shun T, Leimgruber S, Reed R, et al. (2009) Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen. PLoS Negl Trop Dis 3: e540.
12. Siqueira-Neto JL, Song OR, Oh H, Sohn JH, Yang G, et al. (2010) Antileishmanial high-throughput drug screening reveals drug candidates with new scaffolds. PLoS Negl Trop Dis 4: e675.
13. Pescher P, Blisnick T, Bastin P, Spath GF, (2011) Quantitative proteome profiling informs on phenotypic traits that adapt Leishmania donovani for axenic and intracellular proliferation. Cell Microbiol 13: 978-991.
14. Buades A, Coll B, Morel JM, (2004) On image denoising methods. CMLA.
15. Kuijper A, (2004) On detecting all saddle points in 2D image. Pattern Recognition Letter 25: 1665-1672.
16. Karavelas IM, (2004) A robust and efficient implementation for the segment Voronoi diagram. Proc 1 st Int Symp on Voronoi Diagrams in Science and Engineering pp. 51-62.
17. Suzuki K, Horiba I, Sugie N, (2003) Linear-time connected-component labeling based on sequential local operations. Computer Vision and Image Understanding 89: 1-23.
18. Zhang JH, Chung TD, Oldenburg KR, (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.
19. Seifert K, Escobar P, Croft SL, (2010) In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent. J Antimicrob Chemother 65: 508-511.
20. Gebre-Hiwot A, Tadesse G, Croft SL, Frommel D, (1992) An in vitro model for screening antileishmanial drugs: the human leukaemia monocyte cell line, THP-1. Acta Trop 51: 237-245.
21. Delmas F, Di Giorgio C, Elias R, Gasquet M, Azas N, et al. (2000) Antileishmanial activity of three saponins isolated from ivy, alpha-hederin, beta-hederin and hederacolchiside A1, as compared to their action on mammalian cells cultured in vitro. Planta Med 66: 343-347.
22. Mohamed AM, Taye T, Akuffo HO, (1992) Mechanisms of resistance to Leishmania aethiopica. I. Interferon-gamma in combination with a cytokine (not tumor necrosis factor-alpha) is required, but cannot act alone in the inhibition of intracellular forms of L. aethiopica in THP1 cells. Eur J Immunol 22: 2331-2337.
23. da Luz RI, Vermeersch M, Dujardin JC, Cos P, Maes L, (2009) In vitro sensitivity testing of Leishmania clinical field isolates: preconditioning of promastigotes enhances infectivity for macrophage host cells. Antimicrob Agents Chemother 53: 5197-5203.
24. Vermeersch M, da Luz RI, Tote K, Timmermans JP, Cos P, et al. (2009) In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences. Antimicrob Agents Chemother 53: 3855-3859.
25. van Blitterswijk WJ, Verheij M, (2008) Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Curr Pharm Des 14: 2061-2074.
26. Rijal S, Yardley V, Chappuis F, Decuypere S, Khanal B, et al. (2007) Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome? Microbes Infect 9: 529-535.
27. Payne DJ, Gwynn MN, Holmes DJ, Pompliano DL, (2007) Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 6: 29-40.
28. Sereno D, Cordeiro da Silva A, Mathieu-Daude F, Ouaissi A, (2007) Advances and perspectives in Leishmania cell based drug-screening procedures. Parasitol Int 56: 3-7.
29. Dube A, Gupta R, Singh N, (2009) Reporter genes facilitating discovery of drugs targeting protozoan parasites. Trends Parasitol 25: 432-439.
30. Squina FM, Pedrosa AL, Nunes VS, Cruz AK, Tosi LR, (2007) Shuttle mutagenesis and targeted disruption of a telomere-located essential gene of Leishmania. Parasitology 134: 511-522.
31. Pulido SA, Munoz DL, Restrepo AM, Mesa CV, Alzate JF, et al. (2011) Improvement of the green fluorescent protein reporter system in Leishmania spp. for the in vitro and in vivo screening of antileishmanial drugs. Acta Trop.
32. Bolhassani A, Taheri T, Taslimi Y, Zamanilui S, Zahedifard F, et al. (2011) Fluorescent Leishmania species: development of stable GFP expression and its application for in vitro and in vivo studies. Exp Parasitol 127: 637-645.
33. de Toledo JS, Junqueira dos Santos AF, Rodrigues de Moura T, Antoniazi SA, Brodskyn C, et al. (2009) Leishmania (Viannia) braziliensis transfectants overexpressing the miniexon gene lose virulence in vivo. Parasitol Int 58: 45-50.
34. Carpenter AE, (2007) Image-based chemical screening. Nat Chem Biol 3: 461-465.
35. De Muylder G, Ang KKH, Chen S, Arkin MR, Engel JC, et al. (2011) A Screen against Leishmania Intracellular Amastigotes: Comparison to a Promastigote Screen and Identification of a Host Cell-Specific Hit. PLoS Negl Trop Dis 5: e1253.